Mohit Gupta

Mohit Gupta

Auto-generated profile, based on publicly available information

Mohit Gupta

Thermo Fisher Scientific, South San Francisco, CA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
VSVikas Sharma
Vikas Sharma
MGMohit Gupta
Mohit Gupta
PKPradeep Kumar
Pradeep Kumar
Atul SharmaAtul Sharma
Atul Sharma
Since the discovery of DNA intercalating agents (by Lerman, 1961), a growing number of organic, inorganic, and metallic compounds have been developed to treat life-threatening microbial infections and cancers. Fused-heterocycles are amongst the most important group of compounds that have the ability to interact with DNA. DNA intercalators possess a planar aromatic ring structure that inserts itself between the base pairs of nucleic acids. Once inserted, the aromatic structure makes van der Waals interactions and hydrogen-bonding interactions with the base pairs. The DNA intercalator may also contain an ionizable group that can form ionic interactions with the negatively charged phosphate backbone. After the intercalation, other cellular processes could take place, leading ultimately to cell death. The heterocyclic nucleus present in the DNA intercalators can be considered as a pharmacophore that plays an instrumental role in dictating the affinity and selectivity exhibited by these compounds. In this work, we have carried out a revision of small organic molecules that bind to the DNA molecule via intercalation and cleaving and exert their antitumor activity. A general overview of the most recent results in this area, paying particular attention to compounds that are currently under clinical trials, is provided. Advancement in spectroscopic techniques studying DNA interaction can be examined in-depth, yielding important information on structure-activity relationships. In this comprehensive review, we have focused on the introduction to fused heterocyclic agents with DNA interacting features, from medicinal point of view. The structure-activity relationships points, cytotoxicity data, and binding data and future perspectives of medicinal compounds have been discussed in detail.

3 February 2022 in Chemical Biology & Drug Design
Verified
Journal Article
Closed access
PDF file
VSVikas Sharma
Vikas Sharma
MGMohit Gupta
Mohit Gupta

28 August 2019 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
TWThomas D. Wright
Thomas D. Wright
CRChristopher Raybuck
Christopher Raybuck
ABAkshita Bhatt
Akshita Bhatt
DMDarlene Monlish
Darlene Monlish
SCSuravi Chakrabarty
Suravi Chakrabarty
Jane CavanaughJane Cavanaugh
Jane Cavanaugh

30 July 2019 in Frontiers in Oncology
Verified
Journal Article
Open access
ABAkshita B. Bhatt
Akshita B. Bhatt
MGMohit Gupta
Mohit Gupta
VHVan T. Hoang
Van T. Hoang
SCSuravi Chakrabarty
Suravi Chakrabarty
TWThomas D. Wright
Thomas D. Wright
PFPatrick T. Flaherty
Patrick T. Flaherty
Epithelial to mesenchymal transition (EMT) is a cellular program that converts non-motile epithelial cells into invasive mesenchymal cells. EMT is implicated in cancer metastasis, chemo-resistance, cancer progression, and generation of cancer stem cells (CSCs). Inducing mesenchymal to epithelial transition (MET), the reverse phenomenon of EMT, is proposed as a novel strategy to target triple negative and tamoxifen-resistant breast cancer. Triple negative breast cancer (TNBC) is characterized by the loss of hormone receptors, a highly invasive mesenchymal phenotype, and a lack of targeted therapy. Estrogen receptor-positive breast cancer can be targeted by tamoxifen, an ER antagonist. However, these cells undergo EMT over the course of treatment and develop resistance. Thus, there is an urgent need to develop therapeutic interventions to target these aggressive cancers. In this study, we examined the role of novel diphenylamine analogs in converting the mesenchymal phenotype of MDA-MB-231 TNBC cells to a lesser aggressive epithelial phenotype. Using analog-based drug design, a series of diphenylamine analogs were synthesized and initially evaluated for their effect on E-cadherin protein expression and changes incell morphology, which was quantified by measuring the spindle index (SI) value. Selected compound 1 from this series increases the expression of E-cadherin, a primary marker for epithelial cells, and decreases the mesenchymal markers SOX2, ZEB1, Snail, and vimentin. The increase in epithelial markers and the decrease in mesenchymal markers are consistent with a phenotypic switch from spindle-like morphology to cobblestone-like morphology. Furthermore, Compound 1 decreases spheroid viability, cell migration, and cell proliferation in triple negative BT-549 and tamoxifen-resistant MCF-7 breast cancer cells.

1 July 2018 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
SCSuravi Chakrabarty
Suravi Chakrabarty
DMDarlene A. Monlish
Darlene A. Monlish
MGMohit Gupta
Mohit Gupta
TWThomas D. Wright
Thomas D. Wright
VHVan T. Hoang
Van T. Hoang
JCJane E. Cavanaugh
Jane E. Cavanaugh

4 February 2021 in Current Traditional Medicine
Verified
Journal Article
Closed access
PDF file
MGMohit Gupta
Mohit Gupta
SPSaloni Patel
Saloni Patel
Quinoline and isoquinoline motifs are commonly encountered in natural products of diverse origins. These moderately basic fused-heterocyclic rings containing natural products are adorned with remarkable biological activities with clinical use in various diseases demonstrating nature elegance and creativity. Therefore, these privileged rings have attracted profound interest from the scientific community. In this perspective, we have discussed medicinal chemistry perspective of the natural products containing quinoline and isoquinoline scaffolds.